Aktuelles zur medikamentösen Therapie des rezidivierten/metastasierten Nierenzellkarzinom (mNCC)

Zusammenfassung

Das Nierenzellkarzinom gehört zu den häufigen malignen Tumoren bei weiterhin steigender Inzidenz über die letzten 10 Jahre. Bei zunehmend verbesserter Operationstechniken, Nierenerhalt und minimal invasiven Eingriffen in der Lokaltherapie primär resektabler, nicht metastasierter Stadien, bleiben adjuvante Behandlungskonzepte bislang nicht indiziert und die medikamentöse Therapie den fortgeschritten metastasierten oder rezidivierten Tumoren vorbehalten. Nachdem zu Beginn des Jahrtausends durch den Einsatz von Zytokinen, als erstem Immuntherapeutischen Ansatz, das Gesamtüberleben von Patienten mit Nierenzellkarzinom im median 13 Monate betrug, dominierte über die letzte Dekade die zielgerichtete Therapie mit Angiogeneseinhibitoren in Form von Antikörpern oder Tyrosinkinase-Inhibitoren (TKI), sowie der Therapieoption der mTOR-Inhibition. Demzufolge prägte die Wahl der therapeutischen Sequenztherapie die Diskussionen. Mittlerweile stellt die kombinierte Therapie mit Immun-Checkpoint-Inhibitoren (ICI) in der Erstlinientherapie des metastasierten Nierenzellkarzinoms einen neuen Standard dar und konnte das mediane Gesamtüberleben auf >40 Monate anheben. Tyrosinkinase-Inhibitoren haben als Kombinationspartner und in einzelnen Fällen auch als Monotherapie weiter ihren Stellenwert behalten. Derzeit sind in der Erstlinientherapie des Nierenzellkarzinoms in Deutschland eine rein immunonkologische Kombination und 3 Kombinationen aus jeweils einem Immun-Checkpoint-Inhibitor und einem TKI zugelassen.

Abstract

Renal cell carcinoma is a common malignant tumour, whose incidence is steadily increasing. Whilst operative techniques have recently improved, including possibilities of renal preservation and minimally invasive surgery, no use has been shown for adjuvant treatment strategies. When local therapies are not suitable in relapsed or metastatic disease, medical drug treatment is indicated. The first immunologic treatment for renal cell carcinoma consisted of cytokines and overall survival amounted to a median of 13 months. Over the last decade, tyrosine kinase inhibitors (TKI), which inhibit the tumour vasculature, dominated the therapeutic area and raised the clinical discussion about the best sequential pattern. More recently, checkpoint inhibitors (CPI) have set a new standard as therapeutic tools in renal cell cancer. Modern first-line therapies consist of checkpoint inhibitor-based combinations, which have shifted the median overall survival expectation to >40 months. However, tyrosine kinase inhibitors have retained their therapeutic value as combination partners and also as monotherapy in individual cases. One combined immunotherapy and 3 combinations of a checkpoint inhibitor and a TKI are currently approved in Germany.

Schlüsselwörter

fortgeschrittenes/metastasiertes Nierenzellkarzinom (mRCC) - Immun-Checkpoint-Inhibitoren (CPI) - Tyrosinkinaseinhibitoren (TKI) - Kombinationstherapien

Keywords

advanced/metastatic renal cell carcinoma (mRCC) - checkpoint inhibitors (CPI) - tyrosine kinase inhibitors (TKI) - combined therapy

Publikationsverlauf

Eingereicht: 12. April 2021

Angenommen nach Revision: 15. Juni 2021

Artikel online veröffentlicht:
24. August 2021

• Literatur

• 1 Motzer RJ, Bacik J, Murphy BA. et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20: 289-296 DOI: 10.1200/JCO.2002.20.1.289. (PMID: 11773181)
• 2 Heng DYC, Xie W, Regan MM. et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol 2013; 14: 141-148
• 3 https://www.mdcalc.com/imdc-international-metastatic-rcc-database-consortium-risk-model-metastatic-renal-cell-carcinoma
• 4 Curran MA, Montalvo W, Yagita H. et al. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA 2010; 107: 4275-4280
• 5 Das R, Verma R, Sznol M. et al. Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J Immunol 2015; 194: 950-959 DOI: 10.4049/jimmunol.1401686. (PMID: 25539810)
• 6 Fukumura D, Kloepper J, Amoozgar Z. et al. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Oncol 2018; 15: 325-340 DOI: 10.1038/nrclinonc.2018.29. (PMID: 29508855)
• 7 Läubli H, Müller P, D'Amico L. et al. The multi-receptor inhibitor axitinib reverses tumor-induced immunosuppression and potentiates treatment with immune-modulatory antibodies in preclinical murine models. Cancer Immunol Immunther 2018; 67: 815-824 DOI: 10.1007/s00262-018-2136-x. (PMID: 29487979)
• 8 Drake CG, Stein MN. The Immunobiology of Kidney Cancer. J Clin Oncol 2018; 36: 3547-3552 DOI: 10.1200/JCO.2018.79.2648. (PMID: 30372396)
• 9 Yasuda S, Sho M, Yamato I. et al. Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivo. Clin Exp Immunol 2013; 172: 500-506 DOI: 10.1111/cei.12069. (PMID: 23600839)
• 10 Albiges L, Tannir NM, Burotto M. et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open 2020; 5: e001079 DOI: 10.1136/esmoopen-2020-001079. (PMID: 33246931)
• 11 Motzer RJ, Penkov K, Haanen J. et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med 2019; 380: 1103-1115 DOI: 10.1056/NEJMoa1816047. (PMID: 30779531)
• 12 Rini BI., Plimack ER, Stus V. et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med 2019; 380: 1116-1127 DOI: 10.1056/NEJMoa1816714. (PMID: 30779529)
• 13 Choueiri TK, Powles T, Burotto M. et al. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. New Engl J Med 2021; 384: 829-841 DOI: 10.1056/NEJMoa2026982. (PMID: 33657295)
• 14 Motzer RJ, Alekseev B, Rha SY. et al. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. N Engl J Med 2021; 384 (14) 1289-1300 DOI: 10.1056/NEJMoa2035716. (PMID: 33616314)
• 15 Mori K, Schmidinger M, Quhal F. et al. What is next in second- and later-line treatment of metastatic renal cell carcinoma? review of the recent literature. Curr Opin Urol 2021; 31: 76-284 DOI: 10.1097/MOU.0000000000000867. (PMID: 33742984)
• 16 Bersanelli M, Buti S, Rizzo M. The need for new algorithms of treatment sequencing in clear-cell metastatic renal cell carcinoma. Expert Rev Anticancer Ther 2021; 21: 401-412 DOI: 10.1080/14737140.2021.1861941. (PMID: 33287612)
• 17 Lee CH, Shah AY, Hsieh JJ. et al. 710P Phase II trial of lenvatinib (LEN) + pembrolizumab (PEMBRO) for progressive disease after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell (mcc) renal cell carcinoma (RCC): Results by independent imaging review and subgroup analyses. Ann Oncol 2020; 31: 558-559
• 18 Pal SK, Puente J, Heng DYC. et al. Phase 2 trial of lenvatinib at 2 starting doses + everolimus in renal cell carcinoma (RCC). Presented at 19th Annual Meeting of the International Kidney Cancer Symposium (IKCS 2020); November 6–7, 2020.
• 19 Motzer RJ, Hutson TE, Glen H. et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol 2015; 16: 1473-1482 DOI: 10.1016/S1470-2045(15)00290-9. (PMID: 26482279)
• 20 Motzer RJ, Tannir NM, McDermott DF. et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med 2018; 378: 1277-1290 DOI: 10.1056/NEJMoa1712126. (PMID: 29562145)
• 21 Motzer RJ, Escudier B, McDermott DF. et al. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. J Immunother Cancer 2020; 8: e000891 DOI: 10.1136/jitc-2020-000891. (PMID: 32661118)